Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Antiviral Res ; 199: 105275, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-35248614

RESUMEN

Varicella zoster virus (VZV) causes chicken pox and shingles and is prevalent worldwide. Acyclovir and penciclovir (and its prodrugs) are first-line treatments for VZV infections, but they are not highly potent against VZV and resistance may arise in immunocompromised people on long-term therapy. HPMPC (cidofovir) is active against VZV, but cidofovir is not approved for treating VZV diseases, is nephrotoxic, and is not orally bioavailable. Here, we present the synthesis and evaluation of USC-373, a phosphonate prodrug of HPMPC with activity against VZV and other DNA viruses. In cultured fibroblasts, it was potent against VZV Ellen laboratory strain and was not overtly toxic, with EC50 of 4 nM and CC50 of 0.20 µM, producing a selectivity index of 50. In ARPE-19 cells, USC-373 was effective against VZV-ORF57-Luc wild type strain and the acyclovir-resistant isogenic strain. In human skin organ culture, USC-373 formulated in cocoa butter and applied topically prevented VZV-ORF57-Luc spread without toxicity. In NuSkin mice with human skin xenografts, one daily dose of 3 mg/kg was effective by the subcutaneous route, and one daily dose of 10 mg/kg was effective by the oral route. Remarkably, a 10 mg/kg oral dose given every other day was also effective. USC-373 was well tolerated and mice did not lose weight or show signs of distress. The prodrug modifications of USC-373 increase the potency and oral bioavailability compared to its parent nucleoside analog, HPMPC.


Asunto(s)
Organofosfonatos , Profármacos , Aciclovir/farmacología , Animales , Antivirales/farmacología , Antivirales/uso terapéutico , Cidofovir/farmacología , Herpesvirus Humano 3 , Humanos , Ratones , Técnicas de Cultivo de Órganos , Organofosfonatos/farmacología , Profármacos/farmacología , Proteínas Reguladoras y Accesorias Virales
2.
Sci Rep ; 12(1): 1641, 2022 01 31.
Artículo en Inglés | MEDLINE | ID: mdl-35102178

RESUMEN

H84T BanLec is a molecularly engineered lectin cloned from bananas with broad-spectrum antiviral activity against several RNA viruses. H84T BanLec dimers bind glycoproteins containing high-mannose N-glycans on the virion envelope, blocking attachment, entry, uncoating, and spread. It was unknown whether H84T BanLec is effective against human herpesviruses varicella-zoster virus (VZV), human cytomegalovirus (HCMV), and herpes simplex virus 1 (HSV-1), which express high-mannose N-linked glycoproteins on their envelopes. We evaluated H84T BanLec against VZV-ORF57-Luc, TB40/E HCMV-fLuc-eGFP, and HSV-1 R8411 in cells, skin organ culture, and mice. The H84T BanLec EC50 was 0.025 µM for VZV (SI50 = 4000) in human foreskin fibroblasts (HFFs), 0.23 µM for HCMV (SI50 = 441) in HFFs, and 0.33 µM for HSV-1 (SI50 = 308) in Vero cells. Human skin was obtained from reduction mammoplasties and prepared for culture. Skin was infected and cultured up to 14 days. H84T BanLec prevented VZV, HCMV and HSV-1 spread in skin at 10 µM in the culture medium, and also exhibited dose-dependent antiviral effects. Additionally, H84T BanLec arrested virus spread when treatment was delayed. Histopathology of HCMV-infected skin showed no overt toxicity when H84T BanLec was present in the media. In athymic nude mice with human skin xenografts (NuSkin mice), H84T BanLec reduced VZV spread when administered subcutaneously prior to intraxenograft virus inoculation. This is the first demonstration of H84T BanLec effectiveness against DNA viruses. H84T BanLec may have additional unexplored activity against other, clinically relevant, glycosylated viruses.


Asunto(s)
Antivirales/farmacología , Citomegalovirus/efectos de los fármacos , Infecciones por Herpesviridae/tratamiento farmacológico , Herpesvirus Humano 1/efectos de los fármacos , Herpesvirus Humano 3/efectos de los fármacos , Lectinas de Plantas/farmacología , Enfermedades Cutáneas Virales/tratamiento farmacológico , Piel/virología , Animales , Chlorocebus aethiops , Citomegalovirus/crecimiento & desarrollo , Infecciones por Herpesviridae/virología , Herpesvirus Humano 1/crecimiento & desarrollo , Herpesvirus Humano 3/crecimiento & desarrollo , Ratones Desnudos , Musa/genética , Lectinas de Plantas/genética , Enfermedades Cutáneas Virales/virología , Técnicas de Cultivo de Tejidos , Células Vero , Replicación Viral/efectos de los fármacos
3.
Plant Dis ; 103(12): 3166-3171, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31545698

RESUMEN

Verticillium dahliae, the cause of Verticillium wilt, is a widespread pathogen that affects many crops in California and throughout the world. Cover cropping with leguminous species is often integrated into a rotation scheme for its contribution to soil nitrogen, and can contribute to management of Verticillium wilt provided the chosen crop does not support development of V. dahliae. Seven cool season legumes (faba bean, bell bean, field pea, hairy vetch, common vetch, purple vetch, and woollypod vetch), and three warm season legumes (sesbania, sunn hemp, and black-eyed pea) were evaluated as hosts for reproductive growth of V. dahliae. All 10 legumes were colonized by V. dahliae, while remaining symptomless, when subjected to a root-dip inoculation. Similar results were obtained when plants were grown in infested potting soil, albeit with a lower frequency of infection than in root-dip assays. All tested legumes were also infected in field trials, with the exception of bell bean. Overall, warm season legumes sustained higher rates of infection than cool season legumes. Common vetch was the most extensively colonized of the cool season legumes. Based on the results of this study, legumes may not be an appropriate rotation crop in fields where Verticillium wilt is a problem.


Asunto(s)
Productos Agrícolas , Fabaceae , Verticillium , California , Productos Agrícolas/microbiología , Fabaceae/microbiología , Enfermedades de las Plantas/microbiología , Verticillium/fisiología
4.
Sci Rep ; 9(1): 6677, 2019 04 30.
Artículo en Inglés | MEDLINE | ID: mdl-31040330

RESUMEN

Multidrug-resistant organisms are increasing in healthcare settings, and there are few antimicrobials available to treat infections from these bacteria. Pseudomonas aeruginosa is an opportunistic pathogen in burn patients and individuals with cystic fibrosis (CF), and a leading cause of nosocomial infections. P. aeruginosa is inherently resistant to many antibiotics and can develop resistance to others, limiting treatment options. P. aeruginosa has multiple sigma factors to regulate transcription. The alternative sigma factor, RpoN (σ54), regulates many virulence genes and is linked to antibiotic resistance. Recently, we described a cis-acting peptide, RpoN*, which is a "molecular roadblock", binding consensus promoters at the -24 site, blocking transcription. RpoN* reduces virulence of P. aeruginosa laboratory strains, but its effects in clinical isolates was unknown. We investigated the effects of RpoN* on phenotypically varied P. aeruginosa strains isolated from CF patients. RpoN* expression reduced motility, biofilm formation, and pathogenesis in a P. aeruginosa-C. elegans infection model. Furthermore, we investigated RpoN* effects on antibiotic susceptibility in a laboratory strain. RpoN* expression increased susceptibility to several beta-lactam-based antibiotics in strain P. aeruginosa PA19660 Xen5. We show that using a cis-acting peptide to block RpoN consensus promoters has potential clinical implications in reducing virulence and improving antibiotic susceptibility.


Asunto(s)
Antibacterianos/farmacología , Fibrosis Quística/complicaciones , Farmacorresistencia Bacteriana , Infecciones por Pseudomonas/etiología , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/metabolismo , ARN Polimerasa Sigma 54/antagonistas & inhibidores , Animales , Antibacterianos/uso terapéutico , Biopelículas/efectos de los fármacos , Susceptibilidad a Enfermedades , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Infecciones por Pseudomonas/diagnóstico , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/aislamiento & purificación , Pseudomonas aeruginosa/patogenicidad , ARN Polimerasa Sigma 54/genética , Virulencia
7.
Ann Med Psychol (Paris) ; 152(2): 95-104, 1994 Feb.
Artículo en Francés | MEDLINE | ID: mdl-8085708

RESUMEN

The average length of stay of a difficult and dangerous mentally disordered patient and offender in conditions of maximum security is much longer in England and Wales than it is in France. This difference can be attributed to reasons of history, to national procedures relating to admission, transfer and discharge, to the differing importance attached to the gravity of the admission offence and to the time-lags involved in carrying out the transfer and discharge decisions.


Asunto(s)
Investigación sobre Servicios de Salud , Hospitales Psiquiátricos , Tiempo de Internación/estadística & datos numéricos , Trastornos Mentales/epidemiología , Prisiones , Árboles de Decisión , Inglaterra/epidemiología , Femenino , Psiquiatría Forense , Francia/epidemiología , Capacidad de Camas en Hospitales , Humanos , Tiempo de Internación/tendencias , Masculino , Trastornos Mentales/clasificación , Admisión del Paciente/estadística & datos numéricos , Alta del Paciente/estadística & datos numéricos , Alta del Paciente/tendencias , Transferencia de Pacientes/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Gales/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA